Inspire Investing LLC Increases Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Inspire Investing LLC lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 7.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,024 shares of the company’s stock after buying an additional 913 shares during the quarter. Inspire Investing LLC’s holdings in Omnicell were worth $353,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of OMCL. Charles Schwab Investment Management Inc. boosted its stake in Omnicell by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 483,443 shares of the company’s stock valued at $18,192,000 after acquiring an additional 32,548 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Omnicell by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,067,516 shares of the company’s stock worth $40,173,000 after buying an additional 21,798 shares during the last quarter. Norges Bank acquired a new position in Omnicell during the fourth quarter worth approximately $18,802,000. Eagle Asset Management Inc. lifted its stake in Omnicell by 0.8% in the fourth quarter. Eagle Asset Management Inc. now owns 386,834 shares of the company’s stock valued at $14,557,000 after buying an additional 2,900 shares during the last quarter. Finally, NEOS Investment Management LLC acquired a new stake in shares of Omnicell in the fourth quarter valued at approximately $326,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

NASDAQ OMCL opened at $44.62 on Monday. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -97.00, a PEG ratio of 49.47 and a beta of 0.83. The business’s 50 day moving average is $39.21 and its two-hundred day moving average is $32.31. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $53.37. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the prior year, the company posted $0.29 earnings per share. Omnicell’s quarterly revenue was down 7.4% on a year-over-year basis. Research analysts expect that Omnicell, Inc. will post 0.64 EPS for the current year.

Analyst Upgrades and Downgrades

OMCL has been the topic of a number of recent research reports. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Bank of America upped their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their price target on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $37.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.